10-Q: Retractable Technologies Q1 2026 Net Loss Widens Amid Sales Dip

Retractable Technologies Inc. reported a wider net loss for the first quarter of 2026, with sales declining year-over-year, though international sales saw a significant increase.

Summary

• Retractable Technologies Inc. reported a net loss of $4.23 million for the first quarter ended March 31, 2026, compared to a net loss of $10.50 million in the same period of 2025.
• Sales for the quarter decreased to $7.18 million from $8.30 million in the prior year's first quarter.
• Domestic sales decreased by 20.0% while domestic unit sales decreased by 11.5%.
• International sales increased significantly by 42.4%, driven by EasyPoint needle sales.
• The company experienced an increase in operating expenses, largely due to donation expenses.
• As of March 31, 2026, the company had $2.77 million in cash and cash equivalents.
• The company reduced its workforce by approximately 16% in April 2026, expecting to save $2.2 million annually.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to declining sales, widening operating losses, and ongoing risks associated with tariffs and supply chain disruptions, despite some positive international growth.

Positives

• International sales increased by 42.4% in the first quarter of 2026 compared to the same period in 2025, primarily driven by EasyPoint needle sales.
• Overall unit sales increased by 3.6%.
• The company received approximately $137 thousand in tariff refunds during the first quarter of 2026.
• The company expects to save an estimated $2.2 million annually from a 16% workforce reduction implemented in April 2026.
• The company anticipates increased international sales of VanishPoint syringes and EasyPoint needles in the second half of 2026 following EU MDR certification.

Negatives

• Net loss for the first quarter of 2026 was $4.23 million, an improvement from the prior year's $10.50 million loss, but still a significant loss.
• Sales for the quarter decreased to $7.18 million from $8.30 million in the prior year's first quarter.
• Domestic sales decreased by 20.0% and domestic unit sales decreased by 11.5%.
• Operating expenses increased by 14.0%, primarily due to increased donation expense.
• The company reported a negative gross margin for the period.
• The company has a valuation allowance of $12.4 million against its net deferred tax asset as of March 31, 2026.
• Disclosure controls and procedures were not effective as of March 31, 2026.

Risks

• Tariffs on imported goods from China, particularly syringes and needles, continue to have a material impact on the ability to source finished goods and component parts, affecting results of operations and financial position.
• Uncertainty regarding future tariff rates and affected products due to evolving foreign trade policy.
• Potential disruption in supply if the company becomes unable to purchase products from its Chinese manufacturers or produce them domestically.
• Fluctuations in oil prices, material changes in demand, and production costs can affect results.
• The impact of larger market players in the safety device market.
• The company's ability to maintain patent protection.
• Reliance on third-party manufacturing and supplier arrangements.
• The company's ability to access the market.
• The company's ability to maintain liquidity.
• The potential for increased costs in raw materials, transportation, and workforce, which may not be recoverable through price increases.
• The company's belief that domestic customers retained inventory from vaccination efforts, potentially diminishing demand.
• Changes in public sentiment and acceptance of vaccinations could materially impact the business, even for products unrelated to vaccine administration.

Future Outlook

The company expects international sales of VanishPoint syringes and EasyPoint needles to increase in the second half of 2026 following recent certification under the European Union Medical Device Regulation. The company believes it will have adequate means to meet its short-term needs for at least 12 months, supported by cash reserves and liquid investments. However, liquidity is expected to decline materially over the next 1-3 years due to new tariffs and increased domestic manufacturing costs, with potential reliance on liquidation of equity investments or other assets if cash needs cannot be met.

Management Comments

• "We expect international sales of VanishPoint syringes and EasyPoint needles to increase in the second half of 2026 following the recent certification under the European Union Medical Device Regulation 2017/745 which is required for the sale of medical devices within the European Union."
• "Tariffs are expected to have a continuing material impact on our ability to source finished goods and certain raw materials and component parts, and to our results of operations and financial position."
• "We continue working to lessen the financial impact of the tariffs through strategic ordering of products from our Chinese suppliers and continuing to manufacture 1mL, 3mL, and EasyPoint needles in our domestic manufacturing facility."
• "The adaptations to existing equipment will allow us to produce 0.5 mL syringes domestically. Once operational, we will no longer rely on imports for these products. We currently anticipate that commercial quantities will become available, as market demand necessitates, in the second half of 2026."
• "We believe we will have adequate means to meet our short-term needs to fund operations for at least 12 months from the date of issuance of the financial statements."
• "For the next 1-3 years, we believe our liquidity will decline materially, but we expect that we may be able to satisfy our long-term cash requirements using a combination of cash and liquidation of our equity investments."

Industry Context

StockSavvy.ai notes that Retractable Technologies' performance is significantly influenced by global trade policies, particularly tariffs on goods from China, and the ongoing demand for safety medical devices. The company's efforts to increase domestic production and expand international sales, especially in the EU market, are key strategic responses to these industry dynamics.

Comparison to Industry Standards

• The company's net loss of $4.23 million for Q1 2026, while an improvement from the prior year's loss, indicates ongoing profitability challenges compared to industry leaders in the medical device sector that consistently report profits.
• The 20.0% decrease in domestic sales is a concern, as many medical device companies are focused on expanding their domestic market share.
• The 42.4% increase in international sales is a positive sign, aligning with the trend of global expansion seen in many medical device manufacturers, though specific comparable companies are not detailed in the filing.
• The company's reliance on Chinese manufacturing (61.0% of products) exposes it to geopolitical and trade risks, a factor that competitors with more diversified supply chains may be better positioned to manage.
• The significant investment in property, plant, and equipment ($77.3 million net) suggests a commitment to manufacturing capacity, which is standard for the industry, but the associated overhead costs are impacting profitability.

Corporate Governance

Related Party Transactions

• Royalty expense to shareholder: $656,996 for the three months ended March 31, 2026, and $706,421 for the three months ended March 31, 2025.
• The company pays Thomas J. Shaw, owner of certain patented technology, fifty percent (50%) of revenue from certain sublicensees.
• Thomas J. Shaw is the President, Chairman, and Chief Executive Officer of the company.

Stakeholder Impact

• Shareholders: Increased net loss and potential for declining liquidity over the next 1-3 years may negatively impact shareholder value.
• Employees: A 16% workforce reduction in April 2026 is expected to result in job losses but also aims for annual cost savings.
• Suppliers: Continued reliance on Chinese suppliers for certain products, coupled with tariff impacts, could affect costs and supply chain stability.
• Creditors: The company believes it has adequate means to meet its short-term and foreseeable long-term liquidity needs, but acknowledges potential future declines in liquidity.

Next Steps

• Continue to monitor market demand for products donated as charitable contributions.
• Continue to work to lessen the financial impact of tariffs through strategic ordering and increased domestic production.
• Bring domestic production of 0.5 mL syringes online in the second half of 2026.
• Continue to strengthen review procedures, increase precision in account analyses, and ensure timely preparation and review of reconciliations to improve internal controls.

Key Dates

Recommendation

While the company shows some positive signs in international sales growth and has taken steps to control costs through workforce reduction, the declining domestic sales, negative gross margins, and widening operating loss are significant concerns. The ongoing impact of tariffs and supply chain risks, coupled with the acknowledgment of declining liquidity over the next few years, warrants a cautious 'hold' stance until profitability improves and these risks are better mitigated.

Keywords

Retractable Technologies, SEC Filing, 10-Q, Safety Syringes, Medical Devices, Financial Results, Net Loss, Sales, Tariffs, China Tariffs, Domestic Production, International Sales, Workforce Reduction